Quality of Life in Thai Women Diagnosed Cervical Cancer at King Chulalongkorn Memorial Hospital

This study has been completed.
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by:
Chulalongkorn University
ClinicalTrials.gov Identifier:
NCT00741533
First received: August 25, 2008
Last updated: November 17, 2010
Last verified: November 2010
  Purpose

To study the quality of life of patients earlier diagnosed for cervical cancer and cervical intraepithelial neoplasia (CIN).


Condition
Quality of Life
Cervical Cancer
Cervical Intraepithelial Neoplasia

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Quality of Life in Thai Women Diagnosed Cervical Cancer at King Chulalongkorn Memorial Hospital

Resource links provided by NLM:


Further study details as provided by Chulalongkorn University:

Enrollment: 172
Study Start Date: February 2008
Study Completion Date: July 2009
Primary Completion Date: November 2008 (Final data collection date for primary outcome measure)
Detailed Description:

In Thailand, age standardized incidence is 20.9 per 100,000 women-year. Treatment-related survival gain are experienced by side-effect that may reduce quality of life (QoL). We therefore, study the quality of life of patients earlier diagnosed for cervical cancer patients.

  Eligibility

Ages Eligible for Study:   15 Years to 85 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Cervical intraepithelial neoplasia (CIN) or cervical cancer patients

Criteria

Inclusion Criteria:

  • Thai patients
  • aged more than 15 years old.
  • Diagnosed of cervical intraepithelial neoplasia (CIN) or cervical cancer with pathological confirmation. If she has more than one diseases, the most severe will be considered as diagnosis.
  • Not suffered from confusion or reduced level of consciousness or unable to communicate.

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00741533

Locations
Thailand
King Chulalongkorn Memorial Hospital
Patumwan, Bangkok, Thailand, 10330
Sponsors and Collaborators
Chulalongkorn University
Merck Sharp & Dohme Corp.
Investigators
Principal Investigator: Surasak Taneepanichskul, MD. College of Public Health Sciences, Chulalongkorn University
  More Information

No publications provided

Responsible Party: Dean,College of Public Health Sciences, Chulalongkorn University., College of Public Health Sciences, Chulalongkorn University.
ClinicalTrials.gov Identifier: NCT00741533     History of Changes
Other Study ID Numbers: CPHS-01
Study First Received: August 25, 2008
Last Updated: November 17, 2010
Health Authority: Thailand: Ethical Committee

Additional relevant MeSH terms:
Neoplasms
Uterine Cervical Neoplasms
Cervical Intraepithelial Neoplasia
Carcinoma in Situ
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Uterine Cervical Diseases
Uterine Diseases
Genital Diseases, Female
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type

ClinicalTrials.gov processed this record on July 20, 2014